BriaCell Therapeutics Corp.
BCTX
$4.50
$0.194.41%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.20% | 1.76% | -2.76% | -21.79% | -22.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.51% | 1.32% | -18.38% | -30.76% | -13.86% |
| Operating Income | -12.51% | -1.32% | 18.38% | 30.76% | 13.86% |
| Income Before Tax | -155.59% | -73.48% | -438.49% | -221.90% | 7.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -155.59% | -73.48% | -438.49% | -221.90% | 7.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 148.18% | 139.28% | 74.30% | 95.36% | 60.49% |
| Net Income | -155.67% | -72.99% | -449.14% | -224.13% | 8.05% |
| EBIT | -12.51% | -1.32% | 18.38% | 30.76% | 13.86% |
| EBITDA | -12.65% | -1.32% | 18.49% | 31.16% | 14.23% |
| EPS Basic | 34.97% | 59.87% | -86.45% | -46.50% | 58.21% |
| Normalized Basic EPS | 34.59% | 59.85% | -89.00% | -47.12% | 58.47% |
| EPS Diluted | 34.95% | 59.85% | 53.25% | 55.97% | 80.10% |
| Normalized Diluted EPS | 34.59% | 59.85% | -79.20% | -41.17% | 59.27% |
| Average Basic Shares Outstanding | 781.76% | 567.83% | 287.12% | 120.91% | 59.29% |
| Average Diluted Shares Outstanding | 781.76% | 567.83% | 283.02% | 118.49% | 57.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |